奥替那班

化合物

奥替那班英语:Otenabant;开发代号:CP-945,598)是一种有效且高度选择性的CB1拮抗剂[1]它是由辉瑞公司开发的,用于治疗肥胖症[2]但由于在类似药物利莫那班的临床使用过程中出现问题,对该药物的开发已经停止。[3]

奥替那班
临床资料
ATC码
  • 未分配
识别信息
  • 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
CAS号686344-29-6  checkY
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C25H25Cl2N7O
摩尔质量510.42 g·mol−1
3D模型(JSmol英语JSmol
  • CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
  • InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35) ☒N
  • Key:UNAZAADNBYXMIV-UHFFFAOYSA-N ☒N

参见

编辑

参考资料

编辑
  1. ^ Kim MA, Yun H, Kwak H, Kim J, Lee J. Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist. Tetrahedron. 2008, 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057. 
  2. ^ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. November 2007,. Suppl Endocannabinoid (11): 7–10. PMID 18047036. S2CID 25472128. doi:10.1097/01720610-200711000-00005. 
  3. ^ Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies. www.pfizer.com. [2023-02-24]. (原始内容存档于2018-09-17).